SOUTH SAN FRANCISCO, Calif., Oct. 17 SunesisPharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceuticalcompany developing novel anticancer therapeutics, today announced that thecompany will present data at the AACR-NCI-EORTC International Conference onMolecular Targets and Cancer Therapeutics. This year's conference will beheld October 22-26, 2007 in San Francisco, California.
Preliminary data from Sunesis' ongoing Phase 2 clinical trial of thecompany's lead candidate, SNS-595, in platinum-resistant ovarian cancer willbe featured in a poster session on Tuesday, October 23, 2007. In addition,the company will present non-clinical data on SNS-595's in vivo activity incombination with standard chemotherapies, and on SNS-032, the company'scyclin-dependent kinase (CDK) inhibitor, currently in development forhematologic malignancies.
All posters will be presented in the Moscone Convention Center WestExhibit Hall and will also be available following the conference on theSunesis corporate website at http://www.sunesis.com.
About Sunesis' Oncology Programs
Sunesis has built a rich portfolio of product candidates in oncologyfocused on novel pathways and targets, including inhibition of the cell-cycleand survival signaling. SNS-595, a replication-dependent DNA damaging agent,is currently in two Phase 1b acute leukemia clinical trials and a Phase 2ovarian cancer clinical trial. SNS-032, Sunesis' CDK inhibitor, is beingevaluated in a Phase 1 clinical trial in B-cell malignancies. SNS-314, anAurora kinase inhibitor, is currently being studied in a Phase 1dose-escalating clinical trial in patients with advanced solid tumors. Inaddition, Sunesis is developing novel small molecule inhibitors of Raf kinaseand other oncology kinases in collaboration with Biogen Idec.
About Sunesis Pharmaceuticals
Sunesis is a clinical-stage biopharmaceutical company focused on thediscovery, development and commercialization of novel small moleculetherapeutics for oncology and other serious diseases. Sunesis has built abroad product candidate portfolio through internal discovery and in-licensingof novel cancer therapeutics. Sunesis is advancing its product candidatesthrough in-house research and development efforts and strategic collaborationswith leading pharmaceutical and biopharmaceutical companies. For additionalinformation on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.Tuesday, October 23, 2007 * Poster Session A - Clinical Trials Abstract No. A158 A Phase 2 trial of SNS-595 in women with platinum refractory epithelial ovarian cancer * Poster Session A -Small Molecule Therapeutic Agents: Kinase Inhibitors Abstract No. A258 SNS-032 has potent anti-tumor activity in vivo against human leukemia and multiple myeloma xenografts Wednesday, October 24, 2007 * Poster Session B - Other Small Molecule Therapeutics Abstract No. B285 SNS-595 potentiates the in vivo anti-tumor activity of carboplatin, cisplatin and gemcitabine in solid tumor xenografts
SOURCE Sunesis Pharmaceuticals, Inc.